Physician profile
Morgan Mchugh
NPI 1376192054
$3,384.65
in general payments reported to CMS, 2019-2025
32 companies · $2,297 in 2025
The $2,297 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $266 · 2022: $411 · 2023: $242 · 2024: $169 · 2025: $2,297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,755 · Travel and Lodging: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,755.46 |
| Travel and Lodging | $952.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,995.84 | 2022-2025 | Minimed 780g, Truclear |
| Myovant Sciences INC. | $195.46 | 2021-2022 | |
| Aspira Women'S Health INC | $145.67 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $135.79 | 2023-2024 | Myfembree |
| Tandem Diabetes Care, INC. | $90.20 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $70.38 | 2022-2024 | |
| Abbvie INC. | $62.65 | 2021-2022 | |
| Exeltis, USA INC. | $58.44 | 2021-2024 | Slynd |
| Astellas Pharma US INC | $57.62 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $52.26 | 2023 | |
| Becton, Dickinson and Company | $51.16 | 2022-2023 | Bd Onclarity |
| Therapeuticsmd, INC. | $48.14 | 2021-2022 | |
| Smith+Nephew, INC. | $36.82 | 2021 | |
| Mayne Pharma Commercial LLC | $29.42 | 2023-2024 | |
| Averitas Pharma INC. | $25.67 | 2025 | Qutenza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $24.84 | 2025 | Sublocade |
| Lilly USA, LLC | $24.82 | 2025 | Mounjaro |
| Xeris Pharmaceuticals, INC. | $24.42 | 2025 | Recorlev |
| Corcept Therapeutics | $23.63 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.04 | 2025 | Jardiance |
| Sequel Med Tech, LLC | $21.82 | 2025 | Twiist |
| Intuitive Surgical, INC. | $21.51 | 2021 | |
| Insulet Corporation | $21.43 | 2025 | Omnipod |
| Mannkind Corporation | $20.23 | 2025 | |
| Hologic Sales and Service, LLC | $19.52 | 2025 | Aptima |
| Axonics, INC. | $18.13 | 2024 | Axonics |
| Dexcom, INC. | $17.80 | 2025 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $15.28 | 2021 | |
| Organon LLC | $14.11 | 2024 | |
| Evofem Biosciences, INC. | $13.40 | 2022 | |
| Shield Therapeutics INC | $13.15 | 2022 | |
| Avion Pharmaceuticals | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.